Jw Life Science Corp (234080) — Cash Flow-to-Debt Ratio
Jw Life Science Corp (234080) has a Cash Flow-to-Debt Ratio of 0.15x as of March 2026, meaning its operating cash flow of ₩14.17 Billion could theoretically repay 0% of its total liabilities (₩94.80 Billion) in one year. See 234080 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jw Life Science Corp Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Jw Life Science Corp across 11 annual periods. For the full cash flow conversion analysis, see Jw Life Science Corp (234080) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Jw Life Science Corp (2015–2025)
Year-by-year debt coverage analysis for Jw Life Science Corp. Check 234080 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.42x | ₩40.54 Billion | ₩97.63 Billion | ▲ +2.3% |
| 2024 | 0.41x | ₩50.69 Billion | ₩124.88 Billion | ▲ +4.2% |
| 2023 | 0.39x | ₩37.57 Billion | ₩96.44 Billion | ▲ +210.5% |
| 2022 | 0.13x | ₩14.13 Billion | ₩112.61 Billion | ▼ -63.4% |
| 2021 | 0.34x | ₩30.17 Billion | ₩87.97 Billion | ▼ -36.9% |
| 2020 | 0.54x | ₩46.75 Billion | ₩85.98 Billion | ▲ +76.5% |
| 2019 | 0.31x | ₩24.28 Billion | ₩78.79 Billion | ▼ -21.9% |
| 2018 | 0.39x | ₩36.13 Billion | ₩91.60 Billion | ▲ +72.5% |
| 2017 | 0.23x | ₩22.05 Billion | ₩96.43 Billion | ▲ +45.0% |
| 2016 | 0.16x | ₩16.08 Billion | ₩101.94 Billion | ▼ -40.9% |
| 2015 | 0.27x | ₩25.90 Billion | ₩97.05 Billion | — |